ChhajerR, AliN. Genetically modified organisms and visceral leishmaniasis. Front Immunol, 2014; 5:213.
2.
GoedhartPW, van der VoetH, BaldacchinoF, ArpaiaS. A statistical simulation model for field testing of non-target organisms in environmental risk assessment of genetically modified plants. Ecol Evol, 2014; 4(8):1267-1283.
3.
JurkiewiczA, ZagórskiJ, BujakF, LachowskiS, Florek-ŁuszczkiM. Emotional attitudes of young people completing secondary schools towards genetic modification of organisms (GMO) and genetically modified foods (GMF). Ann Agric Environ Med, 2014; 21(1):205-211.
4.
LiangC, van DijkJP, ScholtensIM, et al.Detecting authorized and unauthorized genetically modified organisms containing vip3A by real-time PCR and next-generation sequencing. Anal Bioanal Chem, 2014; 406(11):2603-2611.
World Health Organization.. Informal Member States Consultation on development of a Global Action Plan (GAP) for tackling antimicrobial resistance. October16, 2014. http://www.who.int/drugresistance/memberstatemeeting/en/. Accessed March12, 2015.
9.
SemenovAV, ElsasJD, GlandorfDC, SchilthuizenM, BoerWF. The use of statistical tools in field testing of putative effects of genetically modified plants on nontarget organisms. Ecol Evol, 2013; 3(8):2739-2750.
10.
BallariRV, MartinA. Assessment of DNA degradation induced by thermal and UV radiation processing: implications for quantification of genetically modified organisms. Food Chem, 2013; 141(3):2130-2136.
11.
BarashJR, ArnonSS. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J Infect Dis, 2014; 209(2):183-191.
12.
RaphaelBH, LautenschlagerM, KalbSR, et al.Analysis of a unique Clostridium botulinum strain from the Southern hemisphere producing a novel type E botulinum neurotoxin subtype. BMC Microbiol, 2012; 12:245.
13.
FranciosaG, MauglianiA, FloridiF, AureliP. A novel type A2 neurotoxin gene cluster in Clostridium botulinum strain Mascarpone. FEMS Microbiol Lett, 2006; 261(1):88-94.
14.
DoverN, BarashJR, HillKK, XieG, ArnonSS. Molecular characterization of a novel botulinum neurotoxin type H gene. J Infect Dis, 2014; 209(2):192-202.
15.
The Lancet Infectious Diseases. Addressing the global health security agenda. Lancet Infect Dis, 2014; 14(4):257.
16.
DiMasiJA, HansenRW, GrabowskiHG. The price of innovation: new estimates of drug development costs. J Health Econ, 2003; 22(2):151-185.
17.
BartlettJG, GilbertDN, SpellbergB. Seven ways to preserve the miracle of antibiotics. Clin Infect Dis, 2013; 56(10):1445-1450.
18.
NesmeJ, CécillonS, DelmontTO, MonierJM, VogelTM, SimonetP. Large-scale metagenomic-based study of antibiotic resistance in the environment. Curr Biol, 2014; 24(10):1096-1100.